Earlier recall could have saved lives
In November of 2007 Bayer's heart surgery drug Trasylol was withdrawn from the market at the request of the Federal Drug Administration (FDA) following a study that found Trasylol increased the risk of kidney damage and death in heart bypass patients. It is now estimated that the Kidney damage inflected by this drug is now resulting in over $1 Billion in health care costs every year for Kidney Damage to individuals. It is important to note that one of the first Trasylol Study's was published in January 2006. However, Bayer failed to disclose or refused to disclose to the FDA until after an advisory panel meeting in September 2006. The study's researcher, Dr. Dennis Mangano, said that 22,000 patients could have been saved if Trasylol had been taken off the market when the January 2006 study was first published. Trasylol was given to around one third of heart bypass surgery patients in the United States.
If you need more information - call us toll free at 1-800-862-1260.
TRADEMARK NOTICE: Trasylol is a trademark of Bayer AG pharmaceuticals.
The Carabin & Shaw Law Firm, its' lawyers and this website is in no way affiliated with Bayer AG pharmaceuticals. The use of this mark is solely for informational and product identification purposes.
